Regeneron's earnings boosted by demand for blockbuster eye drug Eylea
Regeneron Pharmaceuticals Inc.'s stock rose 3% early Tuesday, after the company posted better-than-expected fourth-quarter ...
devdiscourse8h
Breakthrough Smart Drug Delivery System Offers Targeted Relief for Rheumatoid Arthritis
Rheumatoid arthritis (RA) is an autoimmune disorder affecting millions worldwide, causing chronic inflammation, debilitating ...
Regeneron's earnings boosted by more than doubling of U.S. sales of blockbuster eye drug Eylea
Sales of Eylea, which the company co-developed with Bayer (DE:BAYA), rose 2% to $1.495 billion. Sales of the higher-dose, longer-lasting formulation Eylea HD rose 148% to $305 million in the U.S., ...
ophthalmologytimes3h
FDA approves continuous delivery ranibizumab injection (Susvimo) for the treatment of diabetic macular edema
Susvimo 100 mg/mL for intravitreal use via ocular implant is a refillable implant surgically inserted into the eye during a ...
Business Wire42m
FDA Approves Genentech’s Susvimo as the First and Only Continuous Delivery Treatment for the Leading Cause of Diabetes-Related Blindness
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug ...
India's JB Chem and Pharma meets Q3 profit view on steady domestic demand
India's J B Chemicals & Pharmaceuticals reported a bigger third-quarter profit on Tuesday, helped by sustained domestic demand for its drugs for chronic and acute conditions.
Zacks.com on MSN5h
CHMP Gives Nod to Expanded Use of J&J's Rybrevant & AZN's Imfinzi
Johnson & Johnson JNJ announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use ...
Ever-Growing USA on MSN1h
Joint Glide Claims to Erase Joint Pain with This 7-Second “WD-40 Trick” – Does It Work?
In today’s fast-paced world, joint pain has become a common concern among individuals of all ages, significantly impacting ...